ITM-11 beats everolimus in Phase 3 GEP-NETs trial; ITM plans filing. Drug will compete with Novartis's Lutathera. Both use ...

In its latest move to expand its portfolio, Lantheus Holdings is spending $250 million upfront to buy radiopharma CDMO and ...

Another obesity biotech emerged on Tuesday morning, this time taking a different approach to the GIP antagonism story than ...

Sarepta Therapeutics unveiled new results from the second part of a clinical trial for its Duchenne muscular dystrophy gene ...

The state of Hawaii can proceed with a lawsuit against the three largest pharmacy benefit managers after it updated its ...

Sage Therapeutics rejects Biogen's $469M buyout offer. CEO Barry Greene and board seek alternatives, with Goldman Sachs ...

Maze Therapeutics is eyeing a $113 million initial public offering a little under two months after revealing a $115 million ...

Affini-T Therapeutics appears to have cut staff last week, according to LinkedIn posts from people who say they are or were ...

Pfizer will pay nearly $60 million to settle claims that its subsidiary Biohaven used illegal kickbacks to drive sales of its ...

In a dramatic turnaround from bankruptcy court less than two years ago, Leerink Partners is now on the offensive and hiring ...

Veru says its muscle-maintaining drug preserved more lean mass in older patients taking a GLP-1, but skittish investors ...

Metsera, a well-funded biotech trying to angle toward the front of the obesity medicine pack, has proposed a $250 million IPO ...